Articles tagged with Drug Targets
Vinculin plays a critical role in enabling cell movement by interacting with the actin cytoskeleton. Disrupting this interaction can lead to chaotic cell movement, impacting organ development and cancer progression.
A targeted cancer drug has shown dramatic responses in patients with specific gene mutations, raising questions about the need for expensive Phase III trials. The author argues that a lower bar for approval could streamline the process and bring effective treatments to patients sooner.
Researchers found that full activation of a crucial brain-signaling molecule requires coordinated motion of its segments. The study may reveal additional drug-binding sites on the receptor, aiding the development of drugs for conditions like epilepsy and Parkinson's disease.
Researchers have discovered that two receptors of leukotriene B4 play opposing roles in inflammation, with BLT1 promoting and BLT2 weakening inflammation during an allergic reaction. This finding suggests new approaches to developing anti-asthma and anti-COPD drugs.
A laboratory study shows that a nanotechnology drug called SapC-DOPS crosses the blood-brain barrier and targets brain-tumor cells, retarding growth of tumor blood vessels. The agent also sensitizes hypoxic cells to killing, supporting further development as a novel treatment for glioblastoma.
Researchers developed statistical models to predict which drug is best for a specific individual with a specific disease, considering pharmacokinetics, pharmacodynamics, and genetic factors. The framework will help doctors and pharmacists simulate variables like protein-protein interactions and predict treatment effectiveness.
A study led by the University of Exeter found that 27% of over-70s with type 2 diabetes achieved better glycaemic control through individualized care alone. Researchers introduced a 'one-size-fits-all' approach for older patients, which proved ineffective due to multiple complications.
A recent study published in Nature reveals that septins play a crucial role in activating the calcium channel on T cell surfaces, allowing them to fight disease. This discovery provides new insights into the intricate pathways involved in turning on T cells and could lead to the development of more targeted drugs.
Researchers have discovered a crucial signaling network between EGFR and MCM7 proteins, which plays a key role in DNA replication and cell growth. In breast cancer patients, high expression of Lyn and MCM7 is associated with reduced survival rates, highlighting a potential new target for cancer therapy.
Researchers used nanosensors and advanced imaging techniques to track the spread of pancreatic tumors and monitor the effectiveness of drugs. The study reveals promising results for combination therapies that can enhance drug delivery and improve clinical outcomes.
The new ProteomicsDB contains over 11,000 datasets from human cancer cell lines and tissues, enabling real-time analysis of large data sets. The database provides instant value for researchers to test analytical hypotheses and develop new drugs with reduced side effects.
A protein complex called Mediator, specifically enzyme CDK8, plays a crucial role in tumor cell survival under hypoxic conditions. Inhibiting CDK8 could provide a potential target for cancer-fighting drugs, particularly those targeting HIF1A transcription factor.
A Singapore research team has identified a protein enzyme, MNK kinase, as a key player in the progression of chronic myeloid leukemia (CML) to its deadly terminal stage. The researchers found that targeting this enzyme could help prevent cancer stem cells from developing drug resistance and improve patient survival.
Researchers have discovered a new oncogene, RET rearrangement, which is present in 15.7% of lung adenocarcinoma patients and may be targeted with existing tyrosine-kinase inhibitors. This finding presents a promising treatment option for patients with this specific mutation.
Researchers developed a novel approach to make ovarian cancer cells susceptible to an antitumor drug, potentially improving treatment outcomes. The strategy targets telomeres and shows promise in treating other epithelial cancers.
Two genetic mutations, PDGFRB and NOTCH3, have been identified as potential therapeutic targets for infantile myofibromatosis (IM), a rare and debilitating disorder. Current treatment options involve repeated surgical removal of tumors, which can be invasive and disfiguring.
Researchers successfully targeted doxorubicin to mitochondria, killing cancer cells even those with developed pumps. The study suggests this approach could work with other nucleus-targeting anti-cancer drugs.
Researchers have identified Dkk1 as a key player in the development of atherosclerosis, a condition that causes arteries to become stiff and narrow, leading to impaired blood flow. Targeting Dkk1 signaling may help limit arteriosclerotic disease, according to a new study.
A new osteoporosis treatment combination of denosumab and teriparatide was found to be more effective than individual therapies, increasing bone density in women with osteoporosis. The study showed significant improvements in BMD at the spine, hip, and femoral neck in women treated with the combination therapy.
Researchers at Scripps Research Institute discovered how to control natural gene silencing processes, leading to a powerful new class of drugs against viral infections, cancers and diseases. The study found that guide RNAs can be designed to destabilize or stabilize the miRNA-Argonaute complex.
Scientists from the University of Pennsylvania define a novel mechanism of tumor hypoxia induced by the longitudinal gradient of residual oxygen along tumor vessels as they transverse the tumor. The researchers found large regions of moderate hypoxia that were not easily explained by existing concepts, suggesting a new scale for unders...
Researchers have discovered a previously unknown link between over-stimulation and brain tissue destruction, pointing to a potential drug target. The study identified NOS1AP as the key protein that links nitric oxide production to cell damage.
Researchers have developed a new technique to improve the use of nanoparticles as a drug delivery system. The study found that smaller particles degrade faster in the body than predicted by in vitro measurements. By understanding this degradation, a mathematical model can be developed to optimize nanoparticle-based therapeutic systems.
Researchers used computer simulations to investigate the energy landscape of ion channels, identifying a critical amino acid that regulates their function. The study provides new insights into ion channel mechanisms, which are essential for developing targeted therapies.
A recent study reveals that a protein in our cells, responsible for transporting vital substances, also enables bacterial cells to develop resistance to antibiotics. This mechanism is linked to the development of antibiotic resistance and cancer drug resistance, highlighting the need for new therapeutic strategies.
Researchers at Duke Medicine found a biomarker produced by mast cells can predict severe dengue cases. Asthma drugs targeting mast cells also showed effectiveness in limiting vascular leakage associated with dengue infections.
BIND-014, a targeted docetaxel Accurin candidate, demonstrated encouraging anti-tumor activity and was well-tolerated in 28 heavily-pretreated patients with advanced or metastatic solid tumors. The Phase 1 results established the maximum tolerated dose of 60 mg/m2 and showed signs of stable disease lasting at least four cycles.
BIND-014, a PSMA-targeted nanoparticle containing docetaxel, demonstrated anti-tumor activity in 28 patients with advanced or metastatic solid tumors. The Phase 1 trial showed encouraging signs of effectiveness, including one complete response and five patients with stable disease.
Children with fragile X syndrome showed significant improvements in general behavior, anxiety, and mood-related behaviors after three months of minocycline treatment. The study provides evidence for the efficacy of minocycline as a targeted treatment for fragile X syndrome.
Researchers have mapped tapeworm genomes to identify potential drug targets using existing drugs, which could lead to faster and more effective treatments. The discovery has significant implications for the development of urgently needed therapies for these devastating diseases.
A new study published in Biological Psychiatry found that antipsychotics with high binding affinity of alpha2 adrenergic and M1 muscarinic receptors are associated with a greater risk of stroke in elderly patients. The study also suggests that stroke risk is highest in the initial weeks of treatment and for those with higher daily doses.
A phase IIa study suggests that ORM-12741, a new add-on drug, improves memory scores by 4% in individuals with moderate Alzheimer's disease, while worsening it by 33% in those receiving a placebo. The study found significant benefits in improving brain functions under stressful conditions.
The NEXT trial found biolimus stent to be non-inferior to everolimus stent in target-lesion revascularization and stent thrombosis rates at one year. The study's long-term data will determine if the device's disappearing polymer offers superior benefits over other available stents.
Researchers have discovered a single anti-ageing enzyme that can be targeted by all 117 tested drugs, leading to a new class of anti-ageing medications. The enzymes' activators, such as resveratrol, show promising results in trials for various diseases, including cancer, diabetes and Alzheimer's.
A comprehensive computer model of human metabolism has been developed, connecting the dots between the human genome and metabolism. The Recon 2 model advances understanding of human metabolism in health and disease, enabling identification of biomarkers and prediction of drug side effects.
Researchers identified a molecule called lipoxin A4 that plays a crucial role in resolving airway inflammation in asthma. This discovery provides new direction for developing next-generation asthma therapies to decrease chronic inflammation.
A novel screening method using genetically engineered baker's yeast identifies chemical compounds that target disease-causing parasites without harming human hosts. The approach has shown promise in identifying potential anti-parasitic compounds with high sensitivity, reducing costs, and increasing reproducibility.
A new microscopy technique has allowed scientists to observe protein clusters in living cancer cells, enabling direct measurement of drug effects on target proteins. This breakthrough could significantly improve cancer treatment by reducing collateral damage associated with traditional therapies.
A study reveals how daclatasvir, a hepatitis C drug, targets the NS5A protein and causes rapid viral decline. The research also provides an accurate estimate of the HCV half-life, revealing that the daily viral production is four times larger than previously thought.
Researchers suggest that a small number of cheap generic drugs can treat most non-communicable diseases (NCDs), improving availability in poorer nations. Better selection and sourcing of generics, as well as increased investment and policies, are key to making life-saving medicines affordable to all.
NIH researchers discovered a critical transport system in Staphylococcus aureus that produces deadly toxins, paving the way for new antibiotic treatments. The system, called Pmt, is thought to play a similar role in other staphylococci, such as S. epidermidis.
Researchers have identified a new mechanism by which the bladder senses its level of fullness through integrin proteins. This discovery may lead to the development of new drugs targeting this pathway to treat overactive bladder and incontinence.
Researchers at VCU have discovered a new way to customize and target antipsychotic drugs to treat specific symptoms in psychosis patients. By targeting G-protein receptor complexes, they aim to reduce side effects and improve treatment outcomes.
Two new methods for detecting and measuring the levels of antisense drugs in cells have been developed, allowing researchers to track PMO delivery to individual cells and quantify its presence in tissue. These methods will advance the field of PMO research and provide valid alternatives to current time-consuming detection techniques.
IRHOM2 is a protein that regulates TACE on immune cells, and blocking it could provide an effective treatment for rheumatoid arthritis. Researchers found that mice deficient in IRHOM2 were protected from inflammatory arthritis.
A new study found that metabolic stress can increase the onset of atrial arrhythmias, such as atrial fibrillation, by activating KATP channels in the atria. Blocking these channels with anti-diabetic drugs reversed the effects of metabolic stress and prevented atrial arrhythmia induction.
A team of researchers at the University of Pennsylvania School of Medicine discovered that metformin suppresses glucagon's ability to generate a signaling molecule, pointing to new drug targets. This finding could lead to improved diabetes treatments with reduced side effects.
Researchers have sequenced the genome of Pneumocystis jirovecii, a fungus that causes pneumocystis pneumonia, a common and often deadly infection in immunocompromised individuals. The genome reveals surprising facts about the pathogen's survival and virulence.
Researchers developed a novel approach to deliver cholesterol-conjugated small interfering RNAs (siRNAs) to liver cells using an endosomolytic polymer. The method significantly improves siRNA efficacy for targeted gene silencing, opening new possibilities for disease treatment.
Researchers say targeting extraoral taste receptors in the gut could release hormones that signal fullness, mimicking meal effects and aiding weight loss. Additional studies are needed to identify effective drug targets for obesity treatment.
Researchers have identified a new drug target, 4'-Phosphopantetheinyl Transferase PptT, which is essential for Mycobacterium tuberculosis (Mtb) growth and survival. This discovery offers hope for the development of new TB treatments that can shorten treatment duration and combat drug-resistant strains.
Researchers found that microRNA-218 is low in medulloblastoma patients and its addition stops disease occurrence. The microRNA also affects genes involved in tumor growth and migration, offering potential targets for therapy.
Recent advancements in lung cancer treatment focus on targeting specific genetic mutations, resulting in improved patient response rates (70-80%) compared to traditional chemotherapies. However, challenges remain in securing funding for clinical trials and staying ahead of the disease's rapid mutation rate.
Gladstone researchers propose targeting ApoE4 as a new strategy for treating Alzheimer's disease. They suggest that drugs can correct the shape of the ApoE4 protein, slowing or stopping its progression.
The growing US population and increased life expectancy necessitate new approaches to prostate cancer treatment. Researchers are exploring targeted therapies, immunotherapy, and precision radiation targeting to improve treatment outcomes for older patients.
GSK3-beta activates BACE1, producing amyloid beta that forms plaques, killing neural cells. Disabling GSK3-beta reduces plaque formation and improves memory in mice. A promising target for AD drug research, but its indiscriminate effects pose challenges.
Researchers have discovered how two proteins regulate telomeres, the protective caps on chromosome ends. The POT-1/TTP-1 complex promotes telomerase activity, a key target for anti-cancer drugs.
A recent study found that male malaria parasites can adapt faster to their surroundings, making them harder to treat. Targeting the slower-reproducing female parasites could lead to more effective long-term treatments and prevent parasite breeding.
Researchers discover Arih2 gene essential for immune system function, potentially leading to treatment breakthroughs for chronic infections like HIV and hepatitis. The gene's role in regulating the immune response could lead to new treatments that reinvigorate the immune system and help clear these infections.
Researchers have identified telomerase as a cause of chronic inflammation in human cancers, a key underlying factor for many diseases. Developing drugs to target this enzyme may lead to novel treatments that alleviate common ailments such as cancer and diabetes.